Pharmacology of Aniracetam

Martin, James R.; Haefely, W.

doi:10.1007/bf03258426

Cited by 32 publications

(4 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their development was based on behavior pharmacology, and they showed statistical improvement in cognitive tasks. [247] The drugs which entered the clinics in the 1990s are based on the early noted deficits in the acetylcholine neurotransmitter system and the loss of the cholinergic neurons. They are inhibitors of acetylcholine esterase and provide symptomatic treatment, addressing the cognitive impairments of the patients, but do not target the underlying pathology.…”

Section: The Discovery Of Drugs For Alzheimer's Diseasementioning

confidence: 99%

Alzheimer's Disease: From Pathology to Therapeutic Approaches

2009

View full text Add to dashboard Cite

Mind how you go: The current strategies for the development of therapies for Alzheimer's disease are very diverse. Particular attention is given to the search for inhibitors (see picture for two examples) of the proteolytic enzyme beta- and gamma-secretase, which inhibits the cleavage of the amyloid precursor proteins into amyloid beta peptides, from which the disease-defining deposits of plaque in the brains of Alzheimer's patients originates.Research on senile dementia and Alzheimer's disease covers an extremely broad range of scientific activities. At the recent international meeting of the Alzheimer's Association (ICAD 2008, Chicago) more than 2200 individual scientific contributions were presented. The aim of this Review is to give an overview of the field and to outline its main areas, starting from behavioral abnormalities and visible pathological findings and then focusing on the molecular details of the pathology. The "amyloid hypothesis" of Alzheimer's disease is given particular attention, since the majority of the ongoing therapeutic approaches are based on its theoretical framework.

show abstract

Section: The Discovery Of Drugs For Alzheimer's Diseasementioning

confidence: 99%

Alzheimer's Disease: From Pathology to Therapeutic Approaches

2009

View full text Add to dashboard Cite

show abstract

“…Introduction of aniracetam is usually related to the involvement of AMPA receptor [ 83 ], cholinergic system [ 84 ], and metabotropic receptor [ 85 ], as part of cognition function. Aniracetam, including pyrrolidinone derivative compounds, is established to diminish the cognitive impairment [ 86 ]. Systemic administration of aniracetam improves the cognitive performance observed behaviours, suggesting the involvement of AMPA in the dentate gyrus [ 87 ].…”

Section: Examples Of Nootropicmentioning

confidence: 99%

Establishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural Nootropic

Suliman

Taib

Moklas

et al. 2016

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Nootropics or smart drugs are well-known compounds or supplements that enhance the cognitive performance. They work by increasing the mental function such as memory, creativity, motivation, and attention. Recent researches were focused on establishing a new potential nootropic derived from synthetic and natural products. The influence of nootropic in the brain has been studied widely. The nootropic affects the brain performances through number of mechanisms or pathways, for example, dopaminergic pathway. Previous researches have reported the influence of nootropics on treating memory disorders, such as Alzheimer's, Parkinson's, and Huntington's diseases. Those disorders are observed to impair the same pathways of the nootropics. Thus, recent established nootropics are designed sensitively and effectively towards the pathways. Natural nootropics such as Ginkgo biloba have been widely studied to support the beneficial effects of the compounds. Present review is concentrated on the main pathways, namely, dopaminergic and cholinergic system, and the involvement of amyloid precursor protein and secondary messenger in improving the cognitive performance.

show abstract

“…Ihre Entwicklung basierte auf verhaltenspharmakologischen Studien, und sie zeigten eine statistische Verbesserung bei kognitiven Tests. [247] Nachfolgende Wirkstoffe, die in den 1990er Jahren in die Klinik eingeführt wurden, basieren auf den schon früh bemerkten Defiziten im Acetylcholin-Neurotransmittersystem und dem Verlust an cholinergen Neuronen. Es handelt sich um Inhibitoren der Acetylcholinesterase, die auf eine symptomatische Behandlung der kognitiven Störungen abzielen, nicht aber auf die zugrunde liegende Pathologie.…”

Section: Die Entwicklung Von Alzheimer-therapeutikaunclassified

Die Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen

Jakob‐Roetne

Jacobsen

2009

Angewandte Chemie

View full text Add to dashboard Cite

Die gegenwärtigen Strategien zur Entwicklung von Alzheimer‐Therapien sind breit gefächert. Ein verstärktes Augenmerk gilt der Suche nach Hemmstoffen (siehe Bild für zwei Beispiele) der proteolytischen Enzyme β‐ und γ‐Secretase, die die Spaltung des Amyloid‐Vorläuferproteins in Amyloid‐β‐Peptide inhibieren, aus denen die krankheitstypischen Plaque‐Ablagerungen im Gehirn von Alzheimer‐Patienten entstehen.magnified imageDie Forschungen über Altersdemenz und die Alzheimersche Krankheit umfassen ein sehr breites Feld wissenschaftlicher Aktivitäten. So wurden etwa bei der letztjährigen internationalen Tagung der Alzheimer‐Gesellschaft (ICAD 2008 in Chicago) mehr als 2200 Einzelbeiträge präsentiert. Ziel dieses Aufsatzes ist es, einen zusammenhängenden Überblick über das Gebiet zu präsentieren und die wichtigsten Themen und Forschungstrends aufzuzeigen. Die Ausführungen beginnen mit einer Diskussion von Verhaltensabweichungen und sichtbaren pathologischen Befunden, bevor dann auf die molekularen Details der Pathologie eingegangen wird. Besonderes Augenmerk gilt der “Amyloidhypothese” der Alzheimer‐Krankheit, da sie das theoretische Fundament für die meisten der in der Entwicklung befindlichen therapeutischen Konzepte bildet.

show abstract

Pharmacology of Aniracetam

Cited by 32 publications

References 69 publications

Alzheimer's Disease: From Pathology to Therapeutic Approaches

Alzheimer's Disease: From Pathology to Therapeutic Approaches

Establishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural Nootropic

Die Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen

Contact Info

Product

Resources

About